Business Description
Karuna Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US48576A1007
Description
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 75.67 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 91.22 | |||||
| Beneish M-Score | -9.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -72.8 | |||||
| 3-Year EPS without NRI Growth Rate | -65.4 | |||||
| 3-Year FCF Growth Rate | -58.2 | |||||
| 3-Year Book Growth Rate | 37.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 126.58 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.96 | |||||
| 9-Day RSI | 79.81 | |||||
| 14-Day RSI | 75.4 | |||||
| 6-1 Month Momentum % | 85.97 | |||||
| 12-1 Month Momentum % | 66.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.31 | |||||
| Quick Ratio | 19.31 | |||||
| Cash Ratio | 18.54 | |||||
| Days Sales Outstanding | 38.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.2 | |||||
| Shareholder Yield % | -3.53 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -75653.98 | |||||
| Net Margin % | -66311.93 | |||||
| FCF Margin % | -59439.76 | |||||
| ROE % | -32.8 | |||||
| ROA % | -31.55 | |||||
| ROIC % | -2178.08 | |||||
| ROC (Joel Greenblatt) % | -2897.19 | |||||
| ROCE % | -37.16 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 17359.47 | |||||
| PB Ratio | 10.01 | |||||
| Price-to-Tangible-Book | 10.01 | |||||
| EV-to-EBIT | -22.95 | |||||
| EV-to-Forward-EBIT | -30.41 | |||||
| EV-to-EBITDA | -23.03 | |||||
| EV-to-Forward-EBITDA | -30.49 | |||||
| EV-to-Revenue | 17359.54 | |||||
| EV-to-Forward-Revenue | 202.05 | |||||
| EV-to-FCF | -29.21 | |||||
| Price-to-Net-Current-Asset-Value | 10.18 | |||||
| Price-to-Net-Cash | 10.64 | |||||
| Earnings Yield (Greenblatt) % | -4.36 | |||||
| FCF Yield % | -3.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Karuna Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.654 | ||
| EPS (TTM) ($) | -11.72 | ||
| Beta | 0 | ||
| Volatility % | 71.99 | ||
| 14-Day RSI | 75.4 | ||
| 14-Day ATR ($) | 3.081373 | ||
| 20-Day SMA ($) | 319.9785 | ||
| 12-1 Month Momentum % | 66.08 | ||
| 52-Week Range ($) | 158.375 - 329.99 | ||
| Shares Outstanding (Mil) | 38.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Karuna Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Karuna Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Karuna Therapeutics Inc Frequently Asked Questions
What is Karuna Therapeutics Inc(KRTX)'s stock price today?
The current price of KRTX is $329.83. The 52 week high of KRTX is $329.99 and 52 week low is $158.38.
When is next earnings date of Karuna Therapeutics Inc(KRTX)?
The next earnings date of Karuna Therapeutics Inc(KRTX) is 2024-05-03 Est..
Does Karuna Therapeutics Inc(KRTX) pay dividends? If so, how much?
Karuna Therapeutics Inc(KRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers